Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vir Biotechnology Inc (NQ: VIR ) 7.930 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Vir Biotechnology Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Biotech Stocks And The SVB Collapse — Here's What We Know March 14, 2023 The collapse of SVB will have a big impact on early-stage, venture-backed companies. Via Investor's Business Daily Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023 March 06, 2023 Via Benzinga Vir Biotechnology Gets Price Targets Cuts By Analysts After Q4 Results March 06, 2023 Vir Biotechnology, Inc. (NASDAQ: VIR) reported worse-than-expected Q4 results. Vir Biotechnology posted a Q4 loss of $0.76 per share, versus market expectations of $0.39 per share. The company’s... Via Benzinga The Top 7 Growth Stocks in Biotech March 03, 2023 The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term. Via InvestorPlace Where Vir Biotechnology Stands With Analysts February 24, 2023 Via Benzinga Vir Biotechnology's Earnings Outlook February 22, 2023 Via Benzinga Overview Of Value Stocks In The Healthcare Sector February 20, 2023 Via Benzinga 5 Value Stocks In The Healthcare Sector January 30, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session February 23, 2023 Via Benzinga NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday February 23, 2023 Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose... Via Benzinga Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session February 21, 2023 Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. Via Benzinga Analyst Expectations for Vir Biotechnology's Future January 27, 2023 Via Benzinga 2 Fast-Growing Healthcare Stocks to Buy and Hold December 02, 2022 The innovative companies have made great gains in a short period of time. Via The Motley Fool Earnings Scheduled For February 23, 2023 February 23, 2023 Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. Via Benzinga Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday February 21, 2023 U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 February 21, 2023 Via Benzinga DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday February 21, 2023 Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 21, 2023 Via Benzinga Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out February 14, 2023 Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020. Via Benzinga Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session February 14, 2023 Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,... Via Benzinga Insiders Selling Meta Platforms And 3 Other Stocks February 10, 2023 The Nasdaq dropped by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. Via Benzinga The 7 Most Undervalued Biotech Stocks to Buy in February 2023 February 02, 2023 Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy. Via InvestorPlace 7 Healthcare Stocks That Will Be Big Winners in 2023 January 31, 2023 Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider. Via InvestorPlace Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023 January 27, 2023 Via Benzinga 2 Stocks That Could Turn $100 Into $1,000 by 2028 January 22, 2023 These growth stocks have substantial tailwinds. Via The Motley Fool BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts December 02, 2022 Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding... Via Benzinga European Official Says COVID-19 Booster Uptake Disappointing In The Region November 25, 2022 Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... Via Benzinga After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade November 18, 2022 Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust. Via Benzinga Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says November 16, 2022 Via Benzinga FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting November 15, 2022 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.